Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer Chemotherapy and Pharmacology
Erschienen in: Cancer Chemotherapy and Pharmacology 1/2015

01.01.2015 | Review Article

Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death

verfasst von: Simendra Singh

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Glutathione S-transferases (GSTs) family of enzymes is best known for their cytoprotective role and their involvement in the development of anticancer drug resistance. Recently, emergence of non-detoxifying properties of GSTs has provided them with significant biological importance. Addressing the complex interactions of GSTs with regulatory kinases will help in understanding its precise role in tumor pathophysiology and in designing GST-centered anticancer strategies.

Methods

We reviewed all published literature addressing the detoxification and regulatory roles of GSTs in the altered biology of cancer and evaluating novel agents targeting GSTs for cancer therapy.

Results

The role of GSTs, especially glutathione S-transferase P1 isoform in tumoral drug resistance, has been the cause of intense debate. GSTs have been demonstrated to interact with different protein partners and modulate signaling pathways that control cell proliferation, differentiation and apoptosis. These specific functions of GSTs could lead to the development of new therapeutic approaches and to the identification of some interesting candidates for preclinical and clinical development. This review focuses on the crucial role played by GSTs in the development of resistance to anticancer agents and the major findings regarding the different modes of action of GSTs to regulate cell signaling.
Literatur
1.
Tew KD, Townsend DM (2012) Glutathione S-transferases as determinants of cell survival and death. Antioxid Redox Signal 17:1728–1737PubMedCentralPubMed
2.
Board PG, Menon D (2013) Glutathione transferases, regulators of cellular metabolism and physiology. Biochim Biophys Acta 1830:3267–3288PubMed
3.
Hebert H, Jegerschöld C (2007) The structure of membrane associated proteins in eicosanoid and glutathione metabolism as determined by electron crystallography. Curr Opin Struct Biol 17:396–404PubMed
4.
Hayes JD, Flanagan JU, Jowsey IR (2005) Glutathione transferases. Ann Rev Pharmacol Toxicol 45:51–88
5.
Deponte M (2013) Glutathione catalysis and the reaction mechanisms of glutathione-dependent enzymes. Biochim Biophys Acta 1830:3217–3266PubMed
6.
Wu B, Dong D (2012) Human cytosolic glutathione transferases: structure, function, and drug discovery. Trends Pharmacol Sci 33:656–668PubMed
7.
Dourado DF, Fernandes PA, Pedro A, Ramos MJ (2008) Mammalian cytosolic glutathione transferases. Curr Prot Pept Sci 9:325–337
8.
Oakley A (2011) Glutathione transferases: a structural perspective. Drug Metab Rev 43:138–151PubMed
9.
Dourado DF, Fernandes PA, Mannervik B, Ramos MJ (2008) Glutathione transferase: new model for glutathione activation. Chemistry 14:9591–9598PubMed
10.
Henderson AP, Bleasdale C, Delaney K, Lindstrom AB, Rappaport SM, Waidyanatha S, Watson WP, Golding BT (2005) Evidence for the formation of Michael adducts from reactions of (E, E)-muconaldehyde with glutathione and other thiols. Bioorg Chem 33:363–373PubMed
11.
Di Pietro G, Magno LA, Rios-Santos F (2010) Glutathione S-transferases: an overview in cancer research. Expert Opin Drug Metab Toxicol 6:153–170PubMed
12.
Raijmakers MT, Steegers EA, Peters WH (2001) Glutathione S-transferases and thiol concentrations in embryonic and early fetal tissues. Hum Reprod 16:2445–2450PubMed
13.
Sherratt PJ, Hayes JD (2001) Glutathione S-transferases. In: Ioannides C (ed) Enzyme systems that metabolise drugs and other xenobiotics. Wiley, UK, pp 319–352
14.
Rowe JD, Nieves E, Listowsky I (1997) Subunit diversity and tissue distribution of human glutathione S-transferases: interpretations based on electrospray ionization-MS and peptide sequence-specific antisera. Biochem J 325:481–486PubMedCentralPubMed
15.
Coles BF, Chen G, Kadlubar FF, Radominska-Pandya A (2002) Interindividual variation and organ-specific patterns of glutathione S-transferase alpha, mu, and pi expression in gastrointestinal tract mucosa of normal individuals. Arch Biochem Biophys 403:270–276PubMed
16.
Schnekenburger M, Morceau F, Henry E, Blasius R, Dicato M, Trentesaux C, Diederich M (2006) Transcriptional and post-transcriptional regulation of glutathione S-transferase P1 expression during butyric acid-induced differentiation of K562 cells. Leuk Res 30:561–568PubMed
17.
Oguztuzun S, Abu-Hijleh A, Coban T, Bulbul D, Kilic M, Iscan M (2011) GST isoenzymes in matched normal and neoplastic breast tissue. Neoplasma 58:304–310PubMed
18.
Bostwick DG, Meiers I, Shanks JH (2007) Glutathione S-transferase: differential expression of alpha, mu, and pi isoenzymes in benign prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. Hum Pathol 38:1394–1401PubMed
19.
Townsend D, Tew K (2003) Cancer drugs, genetic variation and the glutathione S-transferase gene family. Am J Pharmacogenomics 3:157–172PubMed
20.
Peklak-Scott C, Smitherman PK, Townsend AJ, Morrow CS (2008) Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther 7:3247–3255PubMedCentralPubMed
21.
Kraggerud SM, Oldenburg J, Alnaes GI, Berg M, Kristensen VN, Fossa SD, Lothe RA (2009) Functional glutathione S-transferase genotypes among testicular germ cell tumor survivors: associations with primary and post-chemotherapy tumor histology. Pharmacogenet Genomics 19:751–759PubMed
22.
Xie P, Liang Y, Liang G, Liu B (2014) Association between GSTP1 Ile105Val polymorphism and glioma risk: a systematic review and meta-analysis. Tumour Biol 35:493–499PubMed
23.
Yao L, Ji G, Gu A, Zhao P, Liu N (2012) An updated pooled analysis of glutathione S-transferase genotype polymorphisms and risk of adult gliomas. Asian Pac J Cancer Prev 13:157–163PubMed
24.
Huang G, Mills L, Worth LL (2007) Expression of human glutathione S-transferase P1 mediates the chemosensitivity of osteosarcoma cells. Mol Cancer Ther 6:1610–1619PubMed
25.
Lovrić E, Gatalica Z, Eyzaguirre E, Kruslin B (2010) Expression of maspin and glutathionine S-transferase-pi in normal human prostate andprostatic carcinomas. Appl Immunohistochem Mol Morphol 18:429–432PubMed
26.
Economopoulos KP, Sergentanis TN (2010) GSTM1, GSTT1, GSTP1, GSTA1 and colorectal cancer risk: a comprehensive meta-analysis. Eur J Cancer 46:1617–1631PubMed
27.
Ahn J, Gammon MD, Santella RM, Gaudet MM, Britton JA, Teitelbaum SL, Terry MB, Neugut AI, Eng SM, Zhang Y, Garza C, Ambrosone CB (2006) Effects of glutathione S-transferase A1 (GSTA1) genotype and potential modifiers on breast cancer risk. Carcinogenesis 27:1876–1882PubMed
28.
van Nguyen T, Janssen MJ, van Oijen MGH, Bergevoet SM, te Morsche RHM, van Asten HAGH, Laheij RJF, Peters WHM, Jansen JBMJ (2010) Genetic polymorphisms in GSTA1, GSTP1, GSTT1, and GSTM1 and gastric cancer risk in a Vietnamese population. Oncology Res 18:349–355
29.
Maekawa K, Hamaguchi T, Saito Y, Tatewaki N, Kurose K, Kaniwa N, Eguchi Nakajima T, Kato K, Yamada Y, Shimada Y, Yoshida T,Kamatani N, Ura T, Saito M, Muro K, Fuse N, Yoshino T, Doi T, Otsu A, Saijo N, Sawada J, Okuda H, Matsumura Y (2011) Genetic variation and haplotype structures of the glutathione S-transferase genes GSTA1 and GSTA2 in Japanese colorectal cancer patients. Drug Metab Pharmacokinet 26:646–658
30.
Martinez V, Kennedy S, Doolan P, Gammell P, Joyce H, Kenny E, Prakash Mehta J, Ryan E, O’Connor R, Crown J, Clynes M, O’Driscoll L (2008) Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue. Breast Cancer Res Treat 110:521–530PubMed
31.
Carlsten C, Sagoo GS, Frodsham AJ, Burke W, Higgins JP (2008) Glutathione S-transferase M1 (GSTM1) polymorphisms and lung cancer: a literature-based systematic HuGE review and meta-analysis. Am J Epidemiol 167:759–774PubMed
32.
Zhou Y, Zhuang W, Yin YQ, Liu GJ, Wu TX, Yao X, Du L, Wei ML, Wu XT, Wang H (2010) Glutathione S-transferase M1 null genotype associated with gastric cancer among Asians. Dig Dis Sci 55:1824–1830PubMed
33.
Gao L-B, Pan X-M, Li L-J, Liang W-B, Bai P, Rao L, Su X-W, Wang T, Zhou B, Wei Y-G, Zhang L (2011) Null genotypes of GSTM1 and GSTT1 contribute to risk of cervical neoplasia: an evidence-based meta-analysis. PLoS ONE 6:e20157PubMedCentralPubMed
34.
Weiss JR, Kopecky KJ, Godwin J, Anderson J, Willman CL, Moysich KB, Slovak ML, Hoque A, Ambrosone CB (2006) Glutathione S-transferase (GSTM1, GSTT1 and GSTA1) polymorphisms and outcomes after treatment for acute myeloid leukemia: pharmacogenetics in Southwest Oncology Group (SWOG) clinical trials. Leukemia 20:2169–2171PubMed
35.
Xu Y, Wang J, Dong W (2014) GSTM3 A/B polymorphism and risk for head and neck cancer: a meta-analysis. PLoS ONE 9:e83851PubMedCentralPubMed
36.
Fryer AA, Ramsay HM, Lovatt TJ, Jones PW, Hawley CM, Nicol DL, Strange RC, Harden PN (2005) Polymorphisms in glutathione S-transferases and non-melanoma skin cancer risk in Australian renal transplant recipients. Carcinogenesis 26:185–191PubMed
37.
Zhang Y, Ni Y, Zhang H, Pan Y, Ma J, Wang L (2012) Association between GSTM1 and GSTT1 allelic variants and head and neck squamous cell carcinoma. PLoS ONE 7:e47579PubMedCentralPubMed
38.
Anantharaman D, Chaubal PM, Kannan S, Bhisey RA, Mahimkar MB (2007) Susceptibility to oral cancer by genetic polymorphisms at CYP1A1, GSTM1 and GSTT1 loci among Indians: tobacco exposure as a risk modulator. Carcinogenesis 28:1455–1462PubMed
39.
de Aguiar ES, Giacomazzi J, Schmidt AV, Bock H, Saraiva-Pereira ML, Schuler-Faccini L, Duarte Filho D, dos Santos PA, Giugliani R, Caleffi M, Camey SA, Ashton-Prolla P (2012) GSTM1, GSTT1, and GSTP1 polymorphisms, breast cancer risk factors and mammographic density in women submitted to breast cancer screening. Rev Bras Epidemiol 15:246–255PubMed
40.
Settheetham-Ishida W, Yuenyao P, Kularbkaew C, Settheetham D, Ishida T (2009) Glutathione S-transferase (GSTM1 and GSTT1) polymorphisms in cervical cancer in Northeastern Thailand. Asian Pac J Can Prev 10:365–368
41.
Howells RE, Redman CW, Dhar KK, Sarhanis P, Musgrove C, Jones PW, Alldersea J, Fryer AA, Hoban PR, Strange RC (1998) Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer. Clin Cancer Res 4:2439–2445PubMed
42.
Özten N, Sunguroğlu A, Bosland MC (2012) Variations in glutathione S-transferase genes influence risk of chronic myeloid leukemia. Hematol Oncol 30:150–155PubMed
43.
Dunna NR, Vure S, Sailaja K, Surekha D, Raghunadharao D, Rajappa S, Vishnupriya S (2013) Deletion of GSTM1 and T1 genes as a risk factor for development of acute leukemia. Asian Pac J Cancer Prev 14:2221–2224PubMed
44.
Nagle CM, Chenevix-Trench G, Spurdle AB, Webb PM (2007) The role of glutathione S-transferase polymorphisms in ovarian cancer survival. Eur J Cancer 43:283–290PubMed
45.
Goekkurt E, Hoehn S, Wolschke C, Wittmer C, Stueber C, Hossfeld DK, Stoehlmacher J (2006) Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)-novel predictors for response and survival in gastric cancer patients. Br J Cancer 94:281–286PubMedCentralPubMed
46.
Ge J, Tian AX, Wang QS, Kong PZ, Yu Y, Li XQ, Cao XC, Feng YM (2013) The GSTP1 105Val allele increases breast cancer risk and aggressiveness but enhances response to cyclophosphamide chemotherapy in North China. PLoS ONE 8:e67589PubMedCentralPubMed
47.
Voso MT, Hohaus S, Guidi F, Fabiani E, D’Alò F, Groner S, Späth D, Doehner K, Leone G, Doehner H, Schlenk RF (2008) Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. Leukemia 22:1685–1691PubMed
48.
Lo HW, Ali-Osman F (2007) Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr Opin Pharmacol 7:367–374PubMed
49.
Li J, Bluth MH (2011) Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy. Pharmacogenom Personal Med 4:11–33
50.
Sau A, Pellizzari Tregno F, Valentino F, Federici G, Caccuri AM (2010) Glutathione transferases and development of new principles to overcome drug resistance. Arch Biochem Biophys 500:116–122PubMed
51.
Ahire S, Kothawade V, Singh S (2012) A review of glutathione S-transferase in drug resistance. Int J Univ Pharm Life Sci 2
52.
Zeng D-F, Zhang J, Zhu L-D, Kong P-Y, Li J-P, Zhang X, Xu W, Wang J-I, Pen X-G, Wang P, Liu S-H (2014) Analysis of drug resistance-associated proteins expressions of patients with the recurrent of acute leukemia via protein microarray technology. Eur Rev Med Pharmacol Sci 18:537–543PubMed
53.
Kolwijck E, Zusterzeel PLM, Roelofs HMJ, Hendriks JC, Peters WHM, Massuger LFAG (2009) GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer. Cancer Epidemiol Biomarkers Prev 18:2176–2181PubMed
54.
Tew KD, Monks A, Barone L, Rosser D, Akerman G, Montali JA, Wheatley JB, Schmidt DE Jr (1996) Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program. Mol Pharm 50:149–159
55.
Suk K (2012) Proteomic analysis of glioma chemoresistance. Kyoungho Suk. Curr Neuropharmacol 10:72–79
56.
Haas S, Pierl C, Harth V, Pesch B, Rabstein S, Brüning T, Ko Y, Hamann U, Justenhoven C, Brauch H, Fischer HP (2006) Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas. Int J Cancer 119:1785–1791PubMed
57.
Grimminger PP, Maus MK, Schneider PM, Metzger R, Hölscher AH, Sugita H, Danenberg PV, Alakus H, Brabender J (2012) Glutathione S-transferase P1 (GST-P1) mRNA expression and DNA methylation is involved in the pathogenesis and prognosis of NSCLC. Lung Cancer 78:87–91PubMed
58.
Tan KL, Jankova L, Chan C, Fung CL, Clarke C, Lin BP, Robertson G, Molloy M, Chapuis PH, Bokey L, Dent OF, Clarke SJ (2011) Clinicopathological correlates and prognostic significance of glutathione S-transferase Pi expression in 468 patients after potentially curative resection of node-positive colonic cancer. Histopathology 59:1057–1070PubMed
59.
Simic T, Savic-Radojevic A, Pljesa-Ercegovac M, Matic M, Mimic-Oka J (2009) Glutathione S-transferases in kidney and urinary bladder tumors. Nat Rev Urol 6:281–289PubMed
60.
Soh Y, Goto S, Kitajima M, Moriyama S, Kotera K, Nakayama T, Nakajima H, Kondo T, Ishimaru T (2005) Nuclear localisation of glutathione S-transferase pi is an evaluation factor for drug resistance in gynaecological cancers. Clin Oncol (R Coll Radiol) 17:264–270
61.
Huang JX, Li FY, Xiao W, Song ZX, Qian RY, Chen P, Salminen E (2009) Expression of thymidylate synthase d glutathione S-transferase pi in patients with esophageal squamous cell carcinoma. World J Gastroenterol 15:4316–4321PubMedCentralPubMed
62.
Geng M, Wang L, Chen X, Cao R, Li P (2013) The association between chemosensitivity and Pgp, GST-π and Topo II expression in gastric cancer. Diagn Pathal 8:198
63.
Finn NA, Findley HW, Kemp ML (2011) A switching mechanism in doxorubicin bioactivation can be exploited to control doxorubicin toxicity. PLoS Comput Biol 7:e1002151PubMedCentralPubMed
64.
Kanwal R, Pandey M, Bhaskaran N, Maclennan GT, Fu P, Ponsky LE, Gupta S (2014) Protection against oxidative DNA damage and stress in human prostate by glutathione S-transferase P1. Mol Carcinog 53:8–18PubMedCentralPubMed
65.
66.
Ebelt ND, Cantrell MA, van den Berg CL (2013) c-Jun N-terminal kinases mediate a wide range of targets in the metastatic cascade. Genes Cancer 4:378–387PubMedCentralPubMed
67.
68.
Adler V, Yin Z, Fuchs SY, Benerza M, Rosario L, Tew KD, Pincus MR, Sardana M, Henderson CJ, Wolf CR, Davis RJ, Ronai Z (1999) Regulation of JNK signaling by GSTp. EMBO J 18:1321–1334PubMedCentralPubMed
69.
Yin Z, Ivanov V, Habelhah H, Tew KD, Ronai Z (2002) Glutathione S-transferase p elicits protection against H2O2-induced cell death via coordinated regulation of stress kinases. Cancer Res 60:4053–4057
70.
Bernardini S, Bellincampi L, Ballerini S, Ranalli M, Pastrol A, Cortese C, Federici G (2002) Role of GST P1-1 in mediating the effect of etoposide on human neuroblastoma cell line Sh-Sy5y. J Cell Biochem 86:340–347PubMed
71.
Chen N, She Q, Bode AM, Dong Z (2002) Differential gene expression profiles of Jnk1- and Jnk2-deficient murine fibroblast cells. Cancer Res 62:1300–1304PubMed
72.
Bubici C, Papa S (2014) JNK signalling in cancer: in need of new, smarter therapeutic targets. Br J Pharmacol 171:24–37PubMed
73.
Sau A, Filomeni G, Pezzola S, D’Aguanno S, Tregno FP, Urbani A, Serra M, Pasello M, Picci P, Federici G, Caccuri AM (2012) Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines. Mol BioSyst 8:994–1006PubMed
74.
Yang Y, Chang J-Z, Singhal SS, Saini M, Pandaya U, Awasthi S, Awasthi YC (2001) Role of glutathione S-transferases in protection against lipid peroxidation. Overexpression of hGSTA2-2 in K562 cells protects against hydrogen peroxide-induced apoptosis and inhibits JNK and caspase 3 activation. J Biol Chem 276:19220–19230PubMed
75.
Cheng J-Z, Singhal SS, Sharma A, Saini M, Yang Y, Awasthi S, Zimniak P, Awasthi YC (2001) Transfection of mGSTA4 in HL-60 cells protects against 4-hydroxynonenal-induced apoptosis by inhibiting JNK-mediated signaling. Arch Biochem Biophys 392:197–207PubMed
76.
Romero L, Andrews K, Lorraine NG, O’Rourke K, Maslem A, Kirby G (2006) Human GSTA1-1 reduces c-Jun N-terminal kinase signalling and apoptosis in Caco-2 cells. Biochem J 400:135–141PubMedCentralPubMed
77.
Shiizaki S, Naguro I, Ichijo H (2013) Activation mechanisms of ASK1 in response to various stresses and its significance in intracellular signaling Adv Biol Regul 53:135–144
78.
Cho SG, Lee YH, Park HS, Ryoo K, Kang KW, Park J, Eom SJ, Kim MJ, Chang TS, Choi SY, Shim J, Kim Y, Dong MS, Lee MJ, Kim SG, Ichijo H, Choi EJ (2001) Glutathione S-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1. J Biol Chem 276:12749–12755PubMed
79.
Dorion S, Lambert H, Landry J (2002) Activation of the p38 signaling pathway by heat shock involves the dissociation of glutathione S-transferase Mu from Ask1. J Biol Chem 34:30792–30797
80.
Wu Y, Fan Y, Xue B, Luo L, Shen J, Zhang S, Jiang Y, Yin Z (2006) Human glutathione S-transferase P1-1 interacts with TRAF2 and regulates TRAF2-ASK1 signals. Oncogene 25:5787–5800PubMed
81.
Lo H-W, Antoun GR, Ali-Osman F (2004) The human glutathione S-transferase P1 protein is phosphorylated and its metabolic function enhanced by the Ser/Thr protein kinases, cAMPdependent protein kinase and protein kinase C, in glioblastoma cells. Cancer Res 64:9131–9138PubMed
82.
Okamura T, Singh S, Buolamwini J, Haystead T, Friedman H, Bigner D, Ali-Osman F (2009) Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor. J Biol Chem 284:16979–16989PubMedCentralPubMed
83.
Singh S, Okamura T, Ali-Osman F (2009) Serine phosphorylation of glutathione S-transferase P1 (GSTP1) by PKCα enhances GSTP1-dependent cisplatin metabolism and resistance in human glioma cells. Biochem Pharmacol 80:1343–1355
84.
Pagano G, Youssoufian H (2003) Fanconi anaemia proteins: major roles in cell protection against oxidative damage. BioEssays 25:589–595PubMed
85.
Cumming RC, Lightfoot J, Beard K, Youssoufian H, O’Brien PJ, Buchwald M (2001) Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1. Nat Med 7:814–820PubMed
86.
Koh J, Ali-Osman F (2007) GSTP1 forms a stable, non-covalent complex with the tissue transglutaminase TGM2 in human glioblastoma cells. Proc Annu Meet Am Assoc Cancer Res 98:4488
87.
Kamran MZ, Patil P, Gude RP (2013) Role of STAT3 in cancer metastasis and translational advances. Biomed Res Int 421821
88.
Wang Y, van Boxel-Dezaire AH, Cheon H, Yang J, Stark GR (2013) STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor. Proc Natl Acad Sci USA 110:16975–16980PubMedCentralPubMed
89.
Kou X, Chen N, Feng Z, Luo L, Yin Z (2013) GSTP1 negatively regulates Stat3 activation in epidermal growth factor signaling. Oncol Lett 5:1053–1057PubMedCentralPubMed
90.
Pastore A, Piemonte F (2012) S-Glutathionylation signaling in cell biology: progress and prospects. Eur J Pharm Sci 46:279–292PubMed
91.
Townsend DM, Manevich Y, He L, Hutchens S, Pazoles CJ, Tew KD (2009) Novel role for glutathione S-transferase pi. Regulator of protein S-glutathionylation following oxidative and nitrosative stress. J Biol Chem 284:436–445PubMedCentralPubMed
92.
Nevalainen TJ (2010) 1-Cysteine peroxiredoxin: a dual-function enzyme with peroxidase and acidic Ca2 + -independent phospholipase A2 activities. Biochimie 92:638–644PubMed
93.
Neumann CA, Cao J, Manevich Y (2009) Peroxiredoxin 1 and its role in cell signaling. Cell Cycle 8:4072–4078PubMed
94.
Ralat LA, Misquitta SA, Manevich Y, Fisher AB, Colman RF (2008) Characterization of the complex of glutathione S-transferase pi and 1-cysteine peroxiredoxin. Arch Biochem Biophys 474:109–118PubMed
95.
Manevich Y, Feinstein SI, Fisher AB (2004) Activation of the antioxidant enzyme 1-CYS peroxiredoxin requires glutathionylation mediated by heterodimerization with πGST. Proc Natl Acad Sci USA 101:3780–3785PubMedCentralPubMed
96.
Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG (2002) The role of nitric oxide in cancer. Cell Res 12:311–320PubMed
97.
Richardson DR, Lok HC (2008) The nitric oxide-iron interplay in mammalian cells: transport and storage of dinitrosyl iron complexes. Biochim Biophys Acta 1780:638–651PubMed
98.
Singh S, Gupta AK (2011) Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies. Cancer Chemother Pharmacol 67:1211–1224PubMed
99.
Pedersen JZ, De Maria F, Turella P, Federici G, Mattei M, Fabrini R, Dawood KF, Massimi M, Caccuri AM, Ricci G (2007) Glutathione transferases sequester toxic dinitrosyl-iron complexes in cells: a protection mechanism against excess nitric oxide. J Biol Chem 282:6364–6371PubMed
100.
Lok HC, Suryo Rahmanto Y, Hawkins CL, Kalinowski DS, Morrow CS, Townsend AJ, Ponka P, Richardson DR (2012) Nitric oxide storage and transport in cells are mediated by glutathione S-transferase P1-1 and multidrug resistance protein 1 via dinitrosyl iron complexes. J Biol Chem 287:607–618PubMedCentralPubMed
101.
van Iersel ML, Ploemen JP, Lo Bello M, Federici G, van Bladeren PJ (1997) Interactions of alpha, beta-unsaturated aldehydes and ketones with human glutathione S-transferase P1-1. Chem Biol Interact 108:67–78PubMed
102.
Tirona RG, Pang KS (1999) Bimolecular glutathione conjugation kinetics of ethacrynic acid in rat liver: in vitro and perfusion studies. J Pharmacol Exp Ther 290:1230–1241PubMed
103.
Morgan AS, Ciaccio PJ, Tew KD, Kauvar LM (1996) Isozyme-specific glutathione S-transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines. Cancer Chemother Pharmacol 37:363–370PubMed
104.
Johansson K, Ito M, Schophuizen CM, Mathew Thengumtharayil S, Heuser VD, Zhang J, Shimoji M, Vahter M, Ang WH, Dyson PJ, Shibata A, Shuto S, Ito Y, Abe H, Morgenstern R (2011) Characterization of new potential anticancer drugs designed to overcome glutathione transferase mediated resistance. Mol Pharm 8:1698–1708PubMed
105.
Rodriguez-Vicente J, Vicente-Ortega V, Canteras-Jordana M (1998) The effects of different antineoplastic agents and of pretreatment by modulators on three melanoma lines. Cancer 82:495–502PubMed
106.
Zhang P, Chen JH, Dong X, Tang MT, Gao LY, Zhao GS, Yu LG, Guo XL (2013) 6r, a novel oxadiazole analogue of ethacrynic acid, exhibits antitumor activity both in vitro and in vivo by induction of cell apoptosis and S-phase arrest. Biomed Pharmacother 67:58–65PubMed
107.
O’Dwyer PJ, LaCreta F, Nash S, Tinsley PW, Schilder R, Clapper ML, Tew KD, Panting L, Litwin S, Comis RL (1991) Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res 51:6059–6065PubMed
108.
Hamilton D, Batist G (2005) TLK-199 (Telik). IDrugs 8:662–669PubMed
109.
O’Brien ML, Vulevic B, Freer S, Boyd J, Shen H, Tew KD (1999) Glutathione peptidomimetic drug modulator of multidrug resistance-associated protein. J Pharmacol Exp Ther 291:1348–1355PubMed
110.
Raza A, Galili N, Callander N, Ochoa L, Piro L, Emanuel P, Williams S, Burris H, Faderl S, Estrov Z, Curtin P, Larson RA, Keck JG, Jones M, Meng L, Brown GL (2009) Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol 2:20PubMedCentralPubMed
111.
Ruscoe JE, Rosario LA, Wang T, Gaté L, Arifoglu P, Wolf CR, Henderson CJ, Ronai Z, Tew KD (2001) Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J Pharmacol Exp Ther 298:339–345PubMed
112.
Tew KD (2005) TLK-286: a novel glutathione S-transferase-activated prodrug. Expert Opin Investig Drugs 14:1047–1054PubMed
113.
Dourado DFAR, Fernandes PA, Ramos MJ, Mannervik B (2013) Mechanism of glutathione transferase P1-1-catalyzed activation of the prodrug canfosfamide (TLK286, TELCYTA). Biochemistry 52:8069–8078PubMed
114.
Xu H, Namgoong S-Y, Roth E, Brown GL, Keck JG (2004) Synergistic effect of TELCYTA™ (TLK286) in combination with paclitaxel, doxorubicin, carboplatin, oxaliplatin, cisplatin, docetaxel, gemcitabine and iressa in human cancer cells. Proc Amer Assoc Cancer Res 45, Abstract #2008
115.
Izbicka E, Lawrence R, Cerna C, Von Hoff DD, Sanderson PE (1997) Activity of TER286 against human tumor colony-forming units. Anticancer Drugs 8:345–348PubMed
116.
Morgan AS, Sanderson PE, Borch RF, Tew KD, Niitsu Y, Takayama T, Von Hoff DD, Izbicka E, Mangold G, Paul C, Broberg U, Mannervik B, Henner WD, Kauvar LM (1998) Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. Cancer Res 58:2568–2575PubMed
117.
Rosen LS, Brown J, Laxa B, Boulos L, Reiswig L, Henner WD, Lum RT, Schow SR, Maack CA, Keck JG, Mascavage JC, Dombroski JA, Gomez RF, Brown GL (2003) Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies. Clin Cancer Res 9:1628–1638PubMed
118.
119.
Liu J, Li C, Qu W, Leslie E, Bonifant CL, Buzard GS, Saavedra JE, Keefer LK, Waalkes MP (2004) Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation. Mol Cancer Ther 3:709–714PubMed
120.
Saavedra JE, Srinivasan A, Buzard GS, Davies KM, Waterhouse DJ, Inami K, Wilde TC, Citro ML, Cuellar M, Deschamps JR, Parrish D, Shami PJ, Findlay VJ, Townsend DM, Tew KD, Singh S, Jia L, Ji X, Keefer LK (2006) PABA/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity. J Med Chem 49:1157–1164PubMed
121.
Findlay VJ, Townsend DM, Saavedra JE, Buzard GS, Citro ML, Keefer LK, Ji X, Tew KD (2004) Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug. Mol Pharmacol 65:1070–1079PubMed
122.
Ricci G, De Maria F, Antonini G, Turella P, Bullo A, Stella L, Filomeni G, Federici G, Caccuri AM (2005) 7-Nitro-2,1,3-benzoxadiazole derivatives, a new class of suicide inhibitors for glutathione S-transferases. Mechanism of action of potential anticancer drugs. J Biol Chem 280:26397–26405PubMed
123.
Mahajan S, Atkins WM (2005) The chemistry and biology of inhibitors and pro-drugs targeted to glutathione S-transferases. Cell Mol Life Sci 62:1221–1233PubMed
124.
Müller J, Sidler D, Nachbur U, Wastling J, Brunner T, Hemphill A (2008) Thiazolides inhibit growth and induce glutathione S-transferase Pi (GSTP1)-dependent cell death in human colon cancer cells. Int J Cancer 123:1797–1806PubMed
125.
Zheng J, Liu G, Tozkoparan B, Wen D (2005) Mechanistic studies of inactivation of glutathione S-transferase Pi isozyme by a haloenol lactone derivative. Med Chem 1:191–198PubMed
126.
Mukanganyama S, Widersten M, Naik YS, Mannervik B, Hasler JA (2002) Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. Int J Cancer 97:700–705PubMed
127.
Lu GD, Shen HM, Chung MC, Ong CN (2007) Critical role of oxidative stress and sustained JNK activation in aloe-emodin-mediated apoptotic cell death in human hepatoma cells. Carcinogenesis 28:1937–1945PubMed
128.
Aoyama T, Kojima F, Yamazaki T, Tatee T, Abe F, Muraoka Y, Naganawa H, Aoyagi T, Takeuchi T (1993) Benastatins C and D, new inhibitors of glutathione S-transferase, produced by Streptomyces sp. MI384-DF12. Production, isolation, structure determination and biological activities. J Antibiot (Tokyo) 46:712–718
Metadaten
Titel
Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death
verfasst von
Simendra Singh
Publikationsdatum
01.01.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 1/2015
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-014-2566-x

Weitere Artikel der Ausgabe 1/2015

Cancer Chemotherapy and Pharmacology 1/2015 Zur Ausgabe

Short Communication

Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors

Original Article

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

Original Article

A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function

Original Article

Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer

Original Article

A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study

Original Article

Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise